Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct a...

Descripción completa

Detalles Bibliográficos
Autores principales: Novembre, Elio, Tosca, Mariangela, Caffarelli, Carlo, Calvani, Mauro, Cardinale, Fabio, Castagnoli, Riccardo, Chiappini, Elena, Cravidi, Claudio, Del Giudice, Michele Miraglia, Duse, Marzia, Licari, Amelia, Manti, Sara, Martelli, Alberto, Ricci, Giampaolo, Pingitore, Giuseppe, Marseglia, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109428/
https://www.ncbi.nlm.nih.gov/pubmed/35578294
http://dx.doi.org/10.1186/s13052-022-01272-z
_version_ 1784708898037432320
author Novembre, Elio
Tosca, Mariangela
Caffarelli, Carlo
Calvani, Mauro
Cardinale, Fabio
Castagnoli, Riccardo
Chiappini, Elena
Cravidi, Claudio
Del Giudice, Michele Miraglia
Duse, Marzia
Licari, Amelia
Manti, Sara
Martelli, Alberto
Ricci, Giampaolo
Pingitore, Giuseppe
Marseglia, Gian Luigi
author_facet Novembre, Elio
Tosca, Mariangela
Caffarelli, Carlo
Calvani, Mauro
Cardinale, Fabio
Castagnoli, Riccardo
Chiappini, Elena
Cravidi, Claudio
Del Giudice, Michele Miraglia
Duse, Marzia
Licari, Amelia
Manti, Sara
Martelli, Alberto
Ricci, Giampaolo
Pingitore, Giuseppe
Marseglia, Gian Luigi
author_sort Novembre, Elio
collection PubMed
description BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.
format Online
Article
Text
id pubmed-9109428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91094282022-05-16 Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) Novembre, Elio Tosca, Mariangela Caffarelli, Carlo Calvani, Mauro Cardinale, Fabio Castagnoli, Riccardo Chiappini, Elena Cravidi, Claudio Del Giudice, Michele Miraglia Duse, Marzia Licari, Amelia Manti, Sara Martelli, Alberto Ricci, Giampaolo Pingitore, Giuseppe Marseglia, Gian Luigi Ital J Pediatr Review BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions. BioMed Central 2022-05-16 /pmc/articles/PMC9109428/ /pubmed/35578294 http://dx.doi.org/10.1186/s13052-022-01272-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Novembre, Elio
Tosca, Mariangela
Caffarelli, Carlo
Calvani, Mauro
Cardinale, Fabio
Castagnoli, Riccardo
Chiappini, Elena
Cravidi, Claudio
Del Giudice, Michele Miraglia
Duse, Marzia
Licari, Amelia
Manti, Sara
Martelli, Alberto
Ricci, Giampaolo
Pingitore, Giuseppe
Marseglia, Gian Luigi
Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
title Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
title_full Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
title_fullStr Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
title_full_unstemmed Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
title_short Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
title_sort management of bnt162b2 mrna covid-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the italian society of pediatric allergy and immunology (siaip)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109428/
https://www.ncbi.nlm.nih.gov/pubmed/35578294
http://dx.doi.org/10.1186/s13052-022-01272-z
work_keys_str_mv AT novembreelio managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT toscamariangela managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT caffarellicarlo managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT calvanimauro managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT cardinalefabio managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT castagnoliriccardo managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT chiappinielena managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT cravidiclaudio managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT delgiudicemichelemiraglia managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT dusemarzia managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT licariamelia managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT mantisara managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT martellialberto managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT riccigiampaolo managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT pingitoregiuseppe managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip
AT marsegliagianluigi managementofbnt162b2mrnacovid19vaccineinchildrenaged511yearswithallergiesasthmaandimmunodeficiencyconsensusoftheitaliansocietyofpediatricallergyandimmunologysiaip

Ejemplares similares